From the Rolling Stone magazine:
The cannabis industry is entering its next evolution - shifting from commodity cultivation to the high-value race for rare cannabinoids, novel compounds and scalable biomanufacturing. The winners may not be the companies growing the most cannabis, but the ones that can engineer and manufacture the molecules nobody else can access. Companies like eXoZymes are helping drive this shift by developing cell-free biomanufacturing platforms designed to produce rare (non-intoxicating) compounds with greater precision, scalability, and efficiency.
Read the full article here..